SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

• Revenue in USD (TTM)2.93m
• Net income in USD-25.30m
• Incorporated1999
• Employees28.00

• Location
  SCYNEXIS Inc1 Evertrust Plaza, 13Th FloorJERSEY CITY 07302-6548United StatesUSA
• Phone+1 (201) 884-5485
• Fax+1 (919) 544-8697
• Websitehttps://www.scynexis.com/